TY - JOUR
T1 - Novel hormonal approaches in prostate cancer
AU - Friedlander, Terence W.
AU - Ryan, Charles
PY - 2009/5/5
Y1 - 2009/5/5
N2 - It is well recognized that the vast majority of prostate cancers rely on activation of the androgen receptor (AR) by circulating androgens for growth and survival. Three proven hormonal strategies to impair AR signaling are decreasing gonadal hormone production, inhibiting androgen-AR interaction, and impairing extragonadal androgen synthesis. In this review, we discuss the current strategies to slow initial and castration-resistant tumor growth through the use of hormonal agents such as the gonadotropin-releasing hormone analogues, antiandrogens, and adrenolytic agents, focusing on defining the optimal timing, combinations, and use of these agents, as well as on novel drug development.
AB - It is well recognized that the vast majority of prostate cancers rely on activation of the androgen receptor (AR) by circulating androgens for growth and survival. Three proven hormonal strategies to impair AR signaling are decreasing gonadal hormone production, inhibiting androgen-AR interaction, and impairing extragonadal androgen synthesis. In this review, we discuss the current strategies to slow initial and castration-resistant tumor growth through the use of hormonal agents such as the gonadotropin-releasing hormone analogues, antiandrogens, and adrenolytic agents, focusing on defining the optimal timing, combinations, and use of these agents, as well as on novel drug development.
UR - http://www.scopus.com/inward/record.url?scp=65349137552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65349137552&partnerID=8YFLogxK
U2 - 10.1007/s11912-009-0032-4
DO - 10.1007/s11912-009-0032-4
M3 - Review article
C2 - 19336015
AN - SCOPUS:65349137552
SN - 1523-3790
VL - 11
SP - 227
EP - 234
JO - Current Oncology Reports
JF - Current Oncology Reports
IS - 3
ER -
